8 year update of ADAURA at
#WCLC26 from
@DrRoyHerbst - with 3y of adjuvant osimertinib in EGFR mutant NSCLC, 8y OS rate 74% vs 58% with OS HR 0.53 and benefit seen across stages: stage IB HR 0.50, stage II HR 0.60, stage IIIA HR 0.49 - reaffirms standard of care.